Norspan (Buprenorphine)

Buprenorphine acts as a high‑affinity partial agonist at mu‑opioid receptors, producing analgesia while limiting the ceiling effect for respiratory depression. It also blocks kappa‑opioid receptors, which can reduce dysphoric effects. When absorbed through the skin from the patch, it provides steady systemic levels that maintain pain relief over several days.

The prescribed dose of Norspan is determined by the treating clinician based on the severity of pain, prior opioid exposure, and individual patient factors. Available patch strengths are 5 µg/h, 10 µg/h, 15 µg/h, and 20 µg/h, each applied for up to seven days before replacement.

Safety data for buprenorphine transdermal patches in pregnancy and lactation are limited. The product should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and it should be prescribed by a specialist familiar with opioid use in these populations.

To order Norspan, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials. The sales team then provides pricing, availability, shipping details (including any cold‑chain requirements), and assists with import documentation.

Compared with full‑agonist opioid patches such as morphine, buprenorphine’s partial agonist profile offers effective analgesia with a lower ceiling for respiratory depression, which can improve safety in opioid‑tolerant patients. Its long‑acting transdermal delivery also reduces dosing frequency, but it may be less suitable for opioid‑naïve individuals who require rapid titration.

Norspan patches should be stored at room temperature, below 25 °C, in their original protective pouch. Keep them away from direct sunlight, moisture, and heat sources. Do not expose the patches to temperatures above the recommended range, as this may affect drug stability and delivery performance.

The patch is applied to clean, dry, hair‑free skin on the upper torso, upper arm, or flank. Press firmly for at least 30 seconds to ensure good contact. The patch remains in place for up to seven days, after which it should be removed and a new patch applied to a different site to avoid skin irritation.

The most serious risks include respiratory depression, especially in opioid‑naïve patients, severe hypotension, opioid withdrawal syndrome if the patch is removed abruptly, and rare but severe skin reactions such as Stevens‑Johnson syndrome. Patients should be monitored closely during initiation and after any dose changes.

Norspan should not be used by individuals with known hypersensitivity to buprenorphine or any patch components, patients with severe uncontrolled respiratory depression, untreated sleep‑apnea syndrome, or those who are not opioid‑tolerant. Caution is also advised in patients with significant hepatic impairment or those taking interacting medications without proper monitoring.